Erasca (ERAS) Insider James Bristol Receives 120k Option Grant

Rhea-AI Filing Summary

On June 26 2025, Director James Arthur Bristol submitted a Form 4 reporting an equity award from Erasca, Inc. (ERAS). The filing shows that on June 24 2025 he received 120,000 stock options with an exercise price of $1.45 per share. All of the options vest simultaneously on June 24 2026, provided he remains in continuous service, and they expire on June 23 2035. No open-market purchases or sales of common stock were disclosed, leaving Bristol’s post-transaction direct derivative holdings at 120,000 options.

The transaction constitutes an incentive grant only; it does not alter the current share float, generate cash proceeds, or affect near-term earnings. Nevertheless, the award ties the director’s future value creation to long-term share-price performance.

Positive

• 120,000 stock options granted at a $1.45 strike price align the director’s compensation with shareholder value creation.

Negative

• None.

Insights

Securities Analyst

TL;DR – Neutral filing: new 120k option grant to ERAS director, no immediate market impact.

The Form 4 is limited to a single option grant: 120,000 options at $1.45 issued on 06/24/25, vesting 06/24/26, expiring 06/23/35. Because there are no concurrent share purchases or sales, the filing does not change the public float or send a valuation signal. The strike price is typically set at prevailing market levels, so there is no implied premium or discount. For investors, the news is governance-related—aligning the director’s incentives—but financially immaterial in the short term.

Corporate Governance Expert

TL;DR – Standard equity-based compensation, aligns director interests; governance impact modest.

The one-year cliff-vesting schedule encourages board continuity until at least June 2026, while the ten-year term provides long-run participation in share appreciation. The absence of staggered vesting or performance hurdles suggests a plain-vanilla option structure, consistent with typical small-cap biotech practices. No red flags such as back-dating or accelerated vesting appear in the disclosure. Overall, the grant is routine and compliant with Section 16 reporting rules.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bristol James Arthur

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	120,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 120,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bristol James Arthur

(Last) (First) (Middle)

C/O ERASCA, INC.

3115 MERRYFIELD ROW, SUITE 300

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Erasca, Inc. [ ERAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$1.45	06/24/2025		A		120,000		06/24/2026(1)	06/23/2035	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. 100% of the options to purchase shares vest on June 24, 2026, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

	/s/ Ebun S. Garner, as Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did Director James Arthur Bristol receive from ERAS?

He was granted 120,000 stock options.

What is the exercise price of the ERAS options reported in the Form 4?

The exercise price is $1.45 per share.

When do the options granted to the ERAS director vest?

They vest 100% on June 24 2026, subject to continuous service.

Did the Form 4 disclose any open-market purchases or sales of ERAS common stock?

No, the filing lists only an incentive option grant and no share transactions.

What is the expiration date of the reported ERAS stock options?

The options expire on June 23 2035.